Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

Abstract: The present invention discloses methods and compositions comprising. Andrographis paniculata extract standardized to contain not less than 10% w/w andrographolides, Polygonum cuspidatum extract standardized to contain not less than 80% w/w resveratrol, Piper nigrum extract standardized to contain 95% w/w piperine, 95% tetrahydrocurcuminoids, vitamins for the management of viral infections, specifically COVID infection. The invention also discloses the use of the compositions in preventing proteolytic activation of viral spike protein by inhibiting the furin enzyme.

Abstract: The invention discloses a composition comprising Cyperus rotundus extract and Passiflora edulis extract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: The disclosed invention relates to a method comprising composition for effective management of peritonitis in a subject. The invention also discloses a method comprising composition for preventing peritonitis mediated multi organ dysfunction and management of inflammation in a subject. The composition disclosed essentially consists of Witharione.

Abstract: The present invention discloses methods and compositions for therapeutic management of obesity and high fat diet induced hyperlipidemia in mammals, using a composition comprising not less than 20% w/w bisdemethoxycurcumin, wherein the composition further comprises of 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin.

Abstract: The present invention discloses a compound, Vanillylidenechloroacetone (VCA)—1-Chloro-4-(4?-hydroxy-3?-methoxy-phenyl)-but-3-en-2-one, and the process of preparing the same. The invention also discloses a process for synthesis of Calebin-A from Vanillylidenechloroacetone.

Abstract: The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Abstract: The invention discloses a composition and method for therapeutically managing a demyelinated disorder through remyelination. The invention includes a composition comprising Withaferin A and Bisdemethoxycurcumin (BDMC), and a pharmaceutically or nutraceutically acceptable excipients, which can be effectively formulated as tablets and capsules. The invention also covers use of composition for effectively managing a demyelinated disorder through remyelination.

Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.

Abstract: The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.

Abstract: The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.

Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

Abstract: The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.

Abstract: The disclosed invention relates to a method and compositions for use in inhibiting proliferation, migration of Fibroblast-like Synoviocytes (FLS) in a subject. The invention also discloses a composition and method for regulating imbalance in T-helper 17 (Th17), T-cell. The composition disclosed comprises 20-50% BDMC, 10-25% w/w DMC and 30-50% w/w curcumin, further comprising boswellic acids and polysaccharides in the range of 35-50% w/w and 35-45% w/w.

Abstract: A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.